Quốc gia: Úc
Ngôn ngữ: Tiếng Anh
Nguồn: Department of Health (Therapeutic Goods Administration)
Mifepristone
MS Health Pty Ltd
Medicine Registered
Mifepristone Linepharma 200 mg Tablet Page 1 of 4 MIFEPRISTONE LINEPHARMA 200 MG TABLET EACH TABLET CONTAINS MIFEPRISTONE 200 MG CONSUMER MEDICINE INFORMATION It is important that all patients receiving this medication are followed up by a medical practitioner, preferably the prescriber, to ensure that the medication has been effective. Even if no adverse events have occurred all patients must receive follow-up 14 to 21 days after taking mifepristone. WHAT IS IN THIS LEAFLET _ _ This leaflet answers some common questions about Mifepristone Linepharma 200 mg tablet. It does not contain all the available information. It does not take the place of talking to your doctor. All medicines have risks and benefits. Your doctor has weighed the risks of you being given Mifepristone Linepharma 200 mg tablet against the expected benefits it will have for you. IF YOU HAVE ANY CONCERNS ABOUT BEING GIVEN THIS MEDICINE, ASK YOUR DOCTOR. KEEP THIS LEAFLET. You may need to read it again. WHAT MIFEPRISTONE LINEPHARMA 200 MG TABLET IS USED FOR Mifepristone Linepharma is an anti- hormone. It acts by blocking the effects of progesterone, a hormone which is needed for pregnancy to continue. Mifepristone Linepharma can therefore be used to terminate a pregnancy. Mifepristone Linepharma is recommended for: 1- The medical termination of pregnancy. It is recommended for use up to 49 days after your last menstrual period. It is given in combination with another medicine called misoprostol, a prostaglandin analogue. 2- The medical termination of a second trimester pregnancy in combination with a prostaglandin analogue. Second trimester means Đọc toàn bộ tài liệu
PRODUCT INFORMATION – MIFEPRISTONE LINEPHARMA 200 MG TABLET _Version 18-09-2012_ _Page 1 of 14_ It is important that all patients receiving this medication are followed up by a medical practitioner, preferably the prescriber, to ensure that the medication has been effective. Even if no adverse events have occurred all patients must receive follow-up 14 to 21 days after taking mifepristone. See _SPECIAL WARNINGS AND PRECAUTIONS FOR USE_ section. NAME OF THE MEDICINE MIFEPRISTONE LINEPHARMA 200 MG TABLET Australian Approved Name (AAN): Mifepristone Chemical Structure: OH CH 3 CH 3 H H H N CH 3 C H 3 O Molecular formula: C 29 H 35 NO 2 Molecular weight: 429.6 CAS Registry Number: _ _84371-65-3 DESCRIPTION White to off-white, round biconvex tablets, diameter 11 mm, with MF debossed on one side of the tablet. Each tablet contains 200 mg of mifepristone. Mifepristone Linepharma 200 mg tablet contains the following excipients: Starch - maize, Povidone, Cellulose - microcrystalline, Silica - colloidal anhydrous and Magnesium stearate. PRODUCT INFORMATION – MIFEPRISTONE LINEPHARMA 200 MG TABLET _Version 18-09-2012_ _Page 2 of 14_ PHARMACOLOGY PHARMACODYNAMIC PROPERTIES Pharmacotherapeutic group: Other Sex Hormone and Modulator of the Reproductive function/ Antiprogestogen. ATC code: GO3XB01 Mifepristone is a synthetic steroid with an antiprogestational action as a result of competition with progesterone at the progesterone receptors. Mifepristone binds to human progesterone receptors with nanomolar affinity. In animals, oral administration was shown to inhibit the action of endogenous or exogenous progesterone in multiple species (rat, mouse, rabbit, dog and m Đọc toàn bộ tài liệu